Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs

Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs

Abstract Background Medications for opioid use disorder such as opioid agonist treatment (OAT, including methadone, buprenorphine) are the gold standard intervention for opioid use disorder (OUD). Persons with OUD have high rates of neurocognitive impairment and psychiatric and substance use disorde...

Full description

Bibliographic Details
Main Authors: Travis M. Scott, Julia Arnsten, James Patrick Olsen, Franchesca Arias, Chinazo O. Cunningham, Monica Rivera Mindt
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Addiction Science & Clinical Practice
Subjects:
Opioid use disorder
Methadone
Buprenorphine/naloxone
Learning and memory
Depression
Comorbid substance use
Online Access:https://doi.org/10.1186/s13722-021-00272-4

Internet

https://doi.org/10.1186/s13722-021-00272-4

Similar Items